1
|
Zinzani P, Santoro A, Gritti G, Brice P, Barr P, Kuruvilla J, Cunningham D, Kline J, Johnson N, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz A. NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.114_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P.L. Zinzani
- Institute of Hematology; “Seràgnoli" Bologna University; Bologna Italy
| | - A. Santoro
- Oncologia medica; Istituto Clinico Humanitas; Rozzano-Milano Italy
| | - G. Gritti
- Hematology and Bone Marrow Transplant Unit; Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - P. Brice
- Service d'Hémato-Oncologie; Hôpital Saint-Louis; Paris France
| | - P.M. Barr
- Dept. of Hematology/Oncology; University of Rochester; Rochester United States
| | - J. Kuruvilla
- Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - D. Cunningham
- Gastrointestinal and Lymphoma Unit; Royal Marsden Hospital; London United Kingdom
| | - J. Kline
- Hematology & Oncology (Cancer); University of Chicago; Chicago United States
| | - N.A. Johnson
- Division of Hematology; Jewish General Hospital; Montréal Canada
| | - N.A. Mehta-Shah
- Department of Oncology; Washington University School of Medicine; St Louis United States
| | - T. Manley
- Seattle Genetics; Bothell United States
| | - S. Francis
- Bristol-Myers Squibb; Princeton United States
| | - M. Sharma
- Bristol-Myers Squibb; Princeton United States
| | - A.J. Moskowitz
- Lymphoma Inpatient Unit; Memorial Sloan Kettering Cancer Center; New York United States
| |
Collapse
|
2
|
Illidge T, Horwitz S, Iyer S, Bartlett N, Kim W, Tilly H, Belada D, Feldman T, Illés Á, Jacobsen E, Hüttmann A, Zinzani P, O'Connor O, Trepicchio W, Miao H, Rao S, Onsum M, Manley T, Advani R. RESPONSE TO A+CHP BY CD30 EXPRESSION IN THE ECHELON-2 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.92_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- T. Illidge
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health; University of Manchester, National Institutes of Health and Research Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital National Health Service Foundation Trust; Manchester United Kingdom
| | - S. Horwitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - S. Iyer
- Department of Lymphoma and Myeloma; Division of Cancer Medicine, MD Anderson Cancer Center; Houston United States
| | - N. Bartlett
- Department of Medicine; Oncology Division, Washington University School of Medicine, Siteman Cancer Center; Saint Louis United States
| | - W. Kim
- Division of Hematology-Oncology; Department of Medicine, Samsung Medical Center; Seoul Republic of Korea
| | - H. Tilly
- Department of Hematology; Centre Henri Becquerel, Université of Rouen Normandie; Rouen France
| | - D. Belada
- 4th Department of Internal Medicine - Haematology; Charles University, Hospital and Faculty of Medicine; Hradec Králové Czech Republic
| | - T. Feldman
- Hematology Division; Hackensack University Medical Center; Hackensack United States
| | - Á. Illés
- Department of Hematology; University of Debrecen, Faculty of Medicine; Debrecen Hungary
| | - E. Jacobsen
- Division of Hematologic Malignancies; Dana-Farber Cancer Institute; Boston United States
| | - A. Hüttmann
- Department of Haematology; Universitatsklinikum Essen; Essen Germany
| | - P. Zinzani
- Institute of Hematology; “Seràgnoli” University of Bologna; Bologna France
| | - O.A. O'Connor
- Department of Medicine; Columbia University Medical Center; New York United States
| | - W. Trepicchio
- Clinical Development; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals Limited; Cambridge United States
| | - H. Miao
- Clinical Development; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals Limited; Cambridge United States
| | - S. Rao
- Development; Seattle Genetics, Inc.; Bothell United States
| | - M. Onsum
- Development; Seattle Genetics, Inc.; Bothell United States
| | - T. Manley
- Development; Seattle Genetics, Inc.; Bothell United States
| | - R. Advani
- Medicine - Med/Oncology; Stanford Cancer Institute; Stanford United States
| |
Collapse
|
3
|
Kelly K, Daw S, Mauz-Körholz C, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger K, Garaventa A, Buffardi S, Brugières L, Harker-Murray P, Cole P, Drachtman R, Manley T, Francis S, Sacchi M, Leblanc T. RESPONSE-ADAPTED TREATMENT WITH NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN YOUNG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 744 SUBGROUP ANALYSES. Hematol Oncol 2019. [DOI: 10.1002/hon.26_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- K.M. Kelly
- Department of Pediatric Oncology; Roswell Park Comprehensive Cancer Center; Buffalo United States
| | - S. Daw
- Paediatric and Adolescent Haemato-Oncology; University College Hospital; London United Kingdom
| | - C. Mauz-Körholz
- Department of Pediatric Hematology and Oncology; University Hospital Justus Liebig University; Giessen Germany
| | - M. Mascarin
- AYA and Pediatric Radiotherapy Unit; IRCCS Centro di Riferimento Oncologico; Aviano Italy
| | - G. Michel
- Service d'Hématologie pédiatrique; CHU de Marseille - Hôpital de la Timone; Maresille France
| | - S. Cooper
- Pediatric Oncology; Johns Hopkins Hospital; Baltimore United States
| | - A. Beishuizen
- Pediatric Oncology/Hematology; Princess Máxima Center for Pediatric Oncology; Utrecht Netherlands
| | - K.J. Leger
- Hematology-Oncology; Seattle Children's Hospital; Seattle United States
| | - A. Garaventa
- UOC Oncologia; Ematologia e Trapianto di Midollo, IRCCS Istituto Giannina Gaslini; Genoa Italy
| | - S. Buffardi
- Paediatric Haemato-Oncology; Santobono-Pausilipon Hospital; Naples Italy
| | - L. Brugières
- Department of Paediatrics; Institut Gustave Roussy; Villejuif France
| | - P. Harker-Murray
- Pediatric Hematology-Oncology; Children's Hospital of Wisconsin; Milwaukee United States
| | - P.D. Cole
- Division of Pediatric Hematology/Oncology; Rutgers Cancer Institute of New Jersey; New Brunswick United States
| | - R.A. Drachtman
- Division of Pediatric Hematology/Oncology; Rutgers Cancer Institute of New Jersey; New Brunswick United States
| | - T. Manley
- Seattle Genetics; Bothell United States
| | - S. Francis
- Bristol-Myers Squibb; Princeton United States
| | - M. Sacchi
- Bristol-Myers Squibb; Princeton United States
| | - T. Leblanc
- Service d'Hématologie Pédiatrique; Hôpital Robert-Debré APHP; Paris France
| |
Collapse
|
4
|
Manley T, Najjar H, Tsaltas J. Endometriosis and the Ureter: Laparoscopic Management and Training. J Minim Invasive Gynecol 2013. [DOI: 10.1016/j.jmig.2013.08.608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
5
|
Najjar H, Manley T, Tsaltas J. Colorectal Endometriosis: Laparoscopic Surgical Management and Training. J Minim Invasive Gynecol 2013. [DOI: 10.1016/j.jmig.2013.08.619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
6
|
Mackintosh CG, Mason PC, Manley T, Baker K, Littlejohn R. Efficacy and pharmacokinetics of febantel and ivermectin in red deer (Cervus elaphus). N Z Vet J 2011; 33:127-31. [PMID: 16031188 DOI: 10.1080/00480169.1985.35194] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
A trial was conducted to determine the efficacy and pharmacokinetics of fehantel and ivermectin in six month-old red deer calves (C. eluphus). Five calves received febantel by mouth at 7.5 mg/kg, five received a subcutaneous injection of ivermectin at 200 microg/kg and five were controls. All calves were killed seven days later and total lung and gastrointestinal worm counts carried out. Febantel was 85 and 99.8% efficient in removing immature and mature Dictyocaulus viviparus, respectively, and ivermectin was 100% efficient in both cases. There was no gastro-intestinal nematodes in any of the treated calves, compared to an average of 619 in the control calves. The metabolism of febantel resulted in plasma levels of fenbendazole, oxfendazole and sulphone for which the common curves fitted by compartmental model peaked at values (standard errors)-of 0.46 (0.03), 0.41 (0.02) and 1.73 (0.07) mg/l after approximately five, nine, and thirteen hours and were undetectable at 30,72 and 120 hours respectively. There was considerable variation among animals in response to ivermectin. The fitted common curve had a peak plasma level of 15.8 (0.08) microg/l at 20 hours after injection, which had dropped to 7.9 (1.1) microg/l seven days after injection. It was estimated that after 15 days plasma levels of ivermectin would not be detectable. It is concluded that the injectable form of ivermectin tested is a highly efficient anthelmintic in deer, and that plasma levels persist for over a week after subcutaneous injection. Fehantel is very efficient against mature D. viviparus in deer, but its reduced efficiency against immature D. viviparus may relate to the deer;s ability to metabolise and excrete benzimidazoles more quickly than sheep and cattle.
Collapse
Affiliation(s)
- C G Mackintosh
- Invermay Agricultural Centre, Private Bag, Mosgiel, New Zealand
| | | | | | | | | |
Collapse
|
7
|
Abstract
Deer pedicles, antecedents of antlers, develop from a specialized periosteum (antlerogenic periosteum) which overlies the lateral crest of the deer frontal bone. The initiation of pedicle growth is triggered by androgen hormones. Thus far, it is not known whether pedicle initiation is caused by direct stimulation of androgen hormones on the antlerogenic periosteum or whether some intermediate mechanisms are necessary. The present study took an in vitro approach to investigate whether sex hormones have direct mitogenic effects on primary cultured antlerogenic periosteal cells (antlerogenic cells). Antlerogenic cells were obtained from two 5-month-old red deer calves. The cells were passaged twice and then treated with testosterone, dihydrotestosterone, and estradiol. The proliferation assays showed that no direct mitogenic effects on the second passage antlerogenic cells could be detected with any of the sex hormone treatments (P > 0.05). Testosterone-binding studies showed that at the second passage, specific testosterone-binding sites were present in the antlerogenic cells. Therefore, we conclude that androgens do not have mitogenic effects on antlerogenic cells in vitro. Our results suggest that pedicle formation may not be the result of direct stimulation of androgen hormones on antlerogenic tissue. Instead, androgen hormones may only allow the process to proceed by increasing the sensitivity of antlerogenic cells to mitogens, e.g., some growth factors.
Collapse
Affiliation(s)
- C Li
- AgResearch Invermay Agricultural Centre, Private Bag 50034, Mosgiel, New Zealand.
| | | | | | | |
Collapse
|
8
|
Adamson AJ, Banks RE, Mothersdale KN, Pritchard RG, Manley T, Tipping AE. 2-(2,6-Difluorophenyl)-1,3-dithiane and 2-(2,6-Difluorophenyl)-1,3-dithiane 1,1,3,3-Tetraoxide. The Role of Oxidation in Locking a Molecular Conformation. Acta Crystallogr C 1995. [DOI: 10.1107/s0108270194011364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
9
|
Anderson P, Caligiuri M, O'Brien C, Manley T, Ritz J, Schlossman SF. Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci U S A 1990; 87:2274-8. [PMID: 2138330 PMCID: PMC53669 DOI: 10.1073/pnas.87.6.2274] [Citation(s) in RCA: 110] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
We recently reported that CD3- natural killer (NK) cells express the zeta chain of the T-cell receptor complex (zeta NK) in association with higher molecular weight structures whose expression differs between individual NK cell clones. Because NK cell cytolytic activity is known to be triggered by perturbation of the type III Fc gamma receptor (CD16), we sought to determine whether this activating molecule is included in the zeta NK molecular complex. Biochemical evidence for a physical association between CD16 and zeta NK was obtained by comparing immunoprecipitates formed using monoclonal antibodies reactive with each of these molecules by SDS/polyacrylamide gel electrophoresis, immunoblotting, and peptide mapping. In both clonal and polyclonal populations of CD3- NK cells, CD16 and zeta NK specifically associated with one another. Functional evidence for a specific association between CD16 and zeta NK in intact cells was obtained by demonstrating a coordinate down-modulation of both of these molecules induced by either phorbol 12-myristate 13-acetate or monoclonal antibodies reactive with CD16. Our results suggest that Fc gamma receptor type III (CD16) is included in the zeta NK complex and that this complex is likely to play an important role in NK cell activation.
Collapse
MESH Headings
- Antibodies, Monoclonal
- Antigens, CD/immunology
- Antigens, Differentiation, B-Lymphocyte/immunology
- Antigens, Differentiation, B-Lymphocyte/metabolism
- Clone Cells
- Down-Regulation
- Flow Cytometry
- Humans
- Immunoblotting
- Immunoglobulin E/immunology
- Killer Cells, Natural/immunology
- Macromolecular Substances
- Peptide Mapping
- Receptors, Antigen, T-Cell/immunology
- Receptors, Fc/immunology
- Receptors, Fc/metabolism
- Receptors, IgE
Collapse
Affiliation(s)
- P Anderson
- Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA
| | | | | | | | | | | |
Collapse
|
10
|
Johannessen JA, Johannessen OM, Svendsen E, Shuchman R, Manley T, Campbell WJ, Josberger EG, Sandven S, Gascard JC, Olaussen T, Davidson K, Van Leer J. Mesoscale eddies in the Fram Strait marginal ice zone during the 1983 and 1984 Marginal Ice Zone Experiments. ACTA ACUST UNITED AC 1987. [DOI: 10.1029/jc092ic07p06754] [Citation(s) in RCA: 154] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
11
|
Abstract
Tin enriched to 84.5% (119)Sn has been used for static nuclear susceptibility thermometry. A calibration in the 2-40 mK range shows that it is linear in T(-1) quite accurately from 2 to 15 mK. The thermometer is easy to use and responds rapidly.
Collapse
Affiliation(s)
- J Babcock
- School of Physics and Astronomy, University of Minnesota, Minneapolis, Minnesota 55455
| | | | | | | |
Collapse
|